BioArctic's partner Eisai receives Hong Kong regulatory approval for Leqembi to treat Alzheimer's disease
BioArctic AB’s (publ), a Swedish research-based biopharma company, announced that its partner Eisai receives approval from the Department of Health in Hong Kong for Leqembi (generic name: lecanemab) for treatment of Alzheimer’s disease (AD). Treatment with …